Epigenomics AG (Epigenomics AG) Change In Receivables : $-0.16 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Change In Receivables?

Epigenomics AG's change in receivables for the quarter that ended in Jun. 2023 was $-0.14 Mil. It means Epigenomics AG's Accounts Receivable increased by $0.14 Mil from Mar. 2023 to Jun. 2023 .

Epigenomics AG's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.01 Mil. It means Epigenomics AG's Accounts Receivable increased by $0.01 Mil from Dec. 2021 to Dec. 2022 .

Epigenomics AG's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.23 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Epigenomics AG's Days Sales Outstanding for the three months ended in Jun. 2023 was 271.35.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Epigenomics AG's liquidation value for the three months ended in Jun. 2023 was $1.55 Mil.

Epigenomics AG Change In Receivables Historical Data

The historical data trend for Epigenomics AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Change In Receivables Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

0.89

0.09

-0.19

0.20

-0.01

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Receivables	Get a 7-Day Free Trial															-	-0.04	0.02	-	-0.14

Epigenomics AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.

Epigenomics AG (OTCPK:EPGNF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Epigenomics AG's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.226	/	0.076	*	91
=	271.35

2. In Ben Graham's calculation of liquidation value, Epigenomics AG's accounts receivable are only considered to be worth 75% of book value:

Epigenomics AG's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.883	-	2.501	+	0.75 * 0.226	+	0.5 * 0
=	1.55

Epigenomics AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020